These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 34667244)
1. Fibrinolytic nanocages dissolve clots in the tumor microenvironment, improving the distribution and therapeutic efficacy of anticancer drugs. Seo J; Do Yoo J; Kim M; Shim G; Oh YK; Park RW; Lee B; Kim IS; Kim S Exp Mol Med; 2021 Oct; 53(10):1592-1601. PubMed ID: 34667244 [TBL] [Abstract][Full Text] [Related]
2. A targeted ferritin-microplasmin based thrombolytic nanocage selectively dissolves blood clots. Seo J; Al-Hilal TA; Jee JG; Kim YL; Kim HJ; Lee BH; Kim S; Kim IS Nanomedicine; 2018 Apr; 14(3):633-642. PubMed ID: 29309907 [TBL] [Abstract][Full Text] [Related]
3. Fibrinolytic Enzyme Cotherapy Improves Tumor Perfusion and Therapeutic Efficacy of Anticancer Nanomedicine. Kirtane AR; Sadhukha T; Kim H; Khanna V; Koniar B; Panyam J Cancer Res; 2017 Mar; 77(6):1465-1475. PubMed ID: 28108516 [TBL] [Abstract][Full Text] [Related]
4. Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban. Varin R; Mirshahi S; Mirshahi P; Klein C; Jamshedov J; Chidiac J; Perzborn E; Mirshahi M; Soria C; Soria J Thromb Res; 2013 Mar; 131(3):e100-9. PubMed ID: 23313382 [TBL] [Abstract][Full Text] [Related]
6. Thrombolytic efficacy of recombinant human microplasmin in a canine model of copper coil-induced coronary artery thrombosis. Dommke C; Turschner O; Stassen JM; Van de Werf F; Lijnen HR; Verhamme P J Thromb Thrombolysis; 2010 Jul; 30(1):46-54. PubMed ID: 19834783 [TBL] [Abstract][Full Text] [Related]
7. Fibrinolytic Enzymes for Thrombolytic Therapy. Kumar SS; Sabu A Adv Exp Med Biol; 2019; 1148():345-381. PubMed ID: 31482506 [TBL] [Abstract][Full Text] [Related]
12. Fibrin clot lysis by thrombolytic agents is impaired in newborns due to a low plasminogen concentration. Andrew M; Brooker L; Leaker M; Paes B; Weitz J Thromb Haemost; 1992 Sep; 68(3):325-30. PubMed ID: 1440499 [TBL] [Abstract][Full Text] [Related]
13. Transport processes in fibrinolysis and fibrinolytic therapy. Blinc A; Francis CW Thromb Haemost; 1996 Oct; 76(4):481-91. PubMed ID: 8902982 [TBL] [Abstract][Full Text] [Related]
14. [Heparin effect on hydrolysis of fibrin clots in a bull and a man with varying fibrinolytic systems]. Makogonenko EM Ukr Biokhim Zh (1978); 1997; 69(5-6):109-16. PubMed ID: 9606832 [TBL] [Abstract][Full Text] [Related]
15. A novel human microplasmin fold: new perspective to thrombosis treatment. Joison AN; Gallo FS Blood Coagul Fibrinolysis; 2011 Apr; 22(3):236-9. PubMed ID: 21245749 [TBL] [Abstract][Full Text] [Related]
16. Biochemical and biophysical conditions for blood clot lysis. Sabovic M; Blinc A Pflugers Arch; 2000; 440(5 Suppl):R134-6. PubMed ID: 11005642 [TBL] [Abstract][Full Text] [Related]
17. Combination targeting of 'platelets + fibrin' enhances clot anchorage efficiency of nanoparticles for vascular drug delivery. Sun M; Miyazawa K; Pendekanti T; Razmi A; Firlar E; Yang S; Shokuhfar T; Li O; Li W; Sen Gupta A Nanoscale; 2020 Nov; 12(41):21255-21270. PubMed ID: 33063812 [TBL] [Abstract][Full Text] [Related]
18. Identification and Characterization of Plasmin-Independent Thrombolytic Enzymes. Hassan MM; Sharmin S; Kim HJ; Hong ST Circ Res; 2021 Feb; 128(3):386-400. PubMed ID: 33292062 [TBL] [Abstract][Full Text] [Related]